SPH-4336 Market Summary

Key Factors Driving SPH-4336 Growth

1. Selective CDK4/6 inhibition addresses a validated cancer pathway: SPH-4336 is an orally bioavailable, selective CDK4/6 inhibitor that blocks RB phosphorylation and prevents the G1-to-S transition, thereby suppressing tumor-cell proliferation. The CDK4/6 pathway is already clinically validated by approved drugs such as palbociclib, ribociclib and abemaciclib, providing a well-established therapeutic rationale. SPH-4336 is being developed as an oral small molecule, potentially enabling convenient chronic treatment in hormone-driven cancers.

2. Promising early clinical activity provides a basis for further development: In the published Phase I study, 29 patients with advanced solid tumors received SPH-4336 at doses of 50–600 mg. No dose-limiting toxicity or maximum tolerated dose was reached. Among 27 evaluable patients, the disease-control rate was 59.3%, median progression-free survival was 3.1 months, and one breast-cancer patient achieved a confirmed partial response lasting 5.6 months. Six patients had PFS exceeding six months, including patients with breast cancer and sarcoma. These results provide preliminary evidence of antitumor activity, although the small, early-stage dataset means efficacy remains unproven.

3. HR-positive/HER2-negative breast cancer offers a major expansion opportunity: Shanghai Pharmaceuticals is developing SPH-4336 in combination with endocrine therapy in HR-positive/HER2-negative locally advanced or metastatic breast cancer. Importantly, one Phase II/III study specifically targets patients whose disease has progressed following a CDK4/6 inhibitor plus endocrine therapy—a clinically important setting where resistance to existing CDK4/6 therapy creates an unmet need. The study has an estimated enrollment of 254 patients and was listed as recruiting in the January 2026 update.

4. Potential first-line positioning could substantially increase the addressable market: SPH-4336 is also being tested with letrozole as first-line treatment for HR-positive/HER2-negative locally advanced or metastatic breast cancer. The Phase II/III study is designed to compare SPH-4336 + letrozole with placebo + letrozole, potentially positioning the drug earlier in the treatment pathway if efficacy is demonstrated. Success in first-line disease would create a much larger commercial opportunity than restricting treatment to patients who have already progressed on previous CDK4/6 therapy.

5. Liposarcoma represents a differentiated orphan-oncology opportunity: SPH-4336 has also been granted FDA Orphan Drug Designation for liposarcoma, providing regulatory and potential commercial advantages for development in this rare cancer. Shanghai Pharmaceuticals has advanced a Phase II study of SPH-4336 in locally advanced/metastatic liposarcoma, including CDK4-positive disease. A separate Phase Ib/IIa study is evaluating SPH-4336 alone or with cadonilimab in advanced solid tumors, including well-differentiated/dedifferentiated liposarcoma. This gives SPH-4336 an opportunity beyond the highly competitive breast-cancer CDK4/6 market.

SPH-4336 Recent Developments

In June 2025, the American Society of Clinical Oncology (ASCO) meeting confirmed the drug's safety and efficacy profile in advanced solid tumors (primarily breast cancer and sarcoma). Escalating from 50 mg to 600 mg once daily, the maximum tolerated dose (MTD) was not reached, and no dose-limiting toxicities occurred. The trial established an overall disease control rate (DCR) of 59.3%, with a recommended Phase II dose of 400 mg. Progression-free survival (PFS) extended past 6 months for breast cancer and sarcoma subsets.

“SPH-4336 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of SPH-4336 for potential indication like Breast cancer, HER2 negative breast cancer, Liposarcoma, and Solid tumours in the 7MM. A detailed picture of SPH-4336’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the SPH-4336 for potential indications. The SPH-4336 market report provides insights about SPH-4336’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current SPH-4336 performance, future market assessments inclusive of the SPH-4336 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of SPH-4336 sales forecasts, along with factors driving its market.

SPH-4336 Drug Summary

SPH-4336 (also known as I-022) is an investigational, orally bioavailable, selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor developed by Shanghai Pharmaceuticals for the treatment of cancer, with clinical development focused particularly on advanced solid tumors and breast cancer. By selectively inhibiting CDK4 and CDK6, SPH-4336 prevents phosphorylation of the retinoblastoma (Rb) protein, thereby blocking the CDK-mediated transition from the G1 phase to the S phase of the cell cycle, leading to cell-cycle arrest and suppression of tumor-cell proliferation. The drug is administered orally and has been investigated in clinical studies involving patients with advanced solid tumors, including breast cancer and tumors involving the central nervous system; its development has also included evaluation in HR-positive/HER2-negative breast cancer and settings involving brain metastases. SPH-4336 is designed as a small-molecule CDK4/6 inhibitor and remains an investigational therapy without marketing approval, with ongoing clinical development aimed at establishing its efficacy, safety, tolerability, pharmacokinetic profile, and potential advantages over currently approved CDK4/6 inhibitors. The report provides SPH-4336’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the SPH-4336 Market Report

The report provides insights into:

• A comprehensive product overview including the SPH-4336 MoA, description, dosage and administration, research and development activities in potential indication like Breast cancer, HER2 negative breast cancer, Liposarcoma, and Solid tumours.
• Elaborated details on SPH-4336 regulatory milestones and other development activities have been provided in SPH-4336 market report.
• The report also highlights SPH-4336‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The SPH-4336 market report also covers the patents information, generic entry and impact on cost cut.
• The SPH-4336 market report contains current and forecasted SPH-4336 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The SPH-4336 market report also features the SWOT analysis with analyst views for SPH-4336 in potential indications.

Methodology

The SPH-4336 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SPH-4336 Analytical Perspective by DelveInsight

• In-depth SPH-4336 Market Assessment

This SPH-4336 sales market forecast report provides a detailed market assessment of SPH-4336 for potential indication like Breast cancer, HER2 negative breast cancer, Liposarcoma, and Solid tumours in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted SPH-4336 sales data uptil 2034.

• SPH-4336 Clinical Assessment

The SPH-4336 market report provides the clinical trials information of SPH-4336 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

SPH-4336 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

SPH-4336 Market Potential & Revenue Forecast

• Projected market size for the SPH-4336 and its key indications
• Estimated SPH-4336 sales potential (SPH-4336 peak sales forecasts)
• SPH-4336 Pricing strategies and reimbursement landscape

SPH-4336 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• SPH-4336 Market positioning compared to existing treatments
• SPH-4336 Strengths & weaknesses relative to competitors

SPH-4336 Regulatory & Commercial Milestones

• SPH-4336 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

SPH-4336 Clinical Differentiation

• SPH-4336 Efficacy & safety advantages over existing drugs
• SPH-4336 Unique selling points

SPH-4336 Market Report Highlights

• In the coming years, the SPH-4336 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The SPH-4336 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence SPH-4336’s dominance.
• Other emerging products for Breast cancer, HER2 negative breast cancer, Liposarcoma, and Solid tumours are expected to give tough market competition to SPH-4336 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of SPH-4336 in potential indications.
• Analyse SPH-4336 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted SPH-4336 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of SPH-4336 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of SPH-4336? How strong is SPH-4336’s clinical and commercial performance?
• What is SPH-4336’s clinical trial status in each individual indications such as Breast cancer, HER2 negative breast cancer, Liposarcoma, and Solid tumours and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SPH-4336 Manufacturers?
• What are the key designations that have been granted to SPH-4336 for potential indications? How are they going to impact SPH-4336’s penetration in various geographies?
• What is the current and forecasted SPH-4336 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of SPH-4336 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to SPH-4336 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is SPH-4336? What is the duration of therapy and what are the geographical variations in cost per patient?